Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.44 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GNRHR | P30968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17166119 | 0.81 | POLB (0.45) | POLBKMT2ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL21523820 | 0.81 | ALDH1A1 (0.49) | KMT2ASMN1; SMN2ALDH1A1MEN1HTT | |
| SCHEMBL4423914 | 0.78 | MAPT (0.57) | KMT2ASTIM1ORAI1ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL2722945 | 0.77 | MAPT (0.56) | KMT2ASTIM1ORAI1ALDH1A1MEN1 | |
| SCHEMBL21523602 | 0.77 | ALDH1A1 (0.58) | KMT2ASMN1; SMN2ALDH1A1MEN1HTT | |
| SCHEMBL21523675 | 0.76 | SCD5 (0.45) | POLBKMT2ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL22619846 | 0.75 | ALDH1A1 (0.62) | POLBKMT2ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL21523690 | 0.74 | KMT2A (0.54) | POLBKMT2ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL21523657 | 0.74 | SCD5 (0.47) | KMT2ASMN1; SMN2ALDH1A1MEN1HTT | |
| SCHEMBL22619675 | 0.73 | HIF1A (0.46) | KMT2ASMN1; SMN2ALDH1A1MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156791-B2 | Pyrazole compounds acting against allergic, immune and inflammatory conditions | GLAXO GROUP LIMITED (GB) | 2015-10-13 | — | — | US | disclosed |
| US-9156791-B2 | Pyrazole compounds acting against allergic, immune and inflammatory conditions | GLAXO GROUP LIMITED (GB) | 2015-10-13 | — | — | US | disclosed |
| US-9149462-B2 | Pyrazole compounds acting against allergic, inflammatory and immune disorders | GLAXO GROUP LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| US-9149462-B2 | Pyrazole compounds acting against allergic, inflammatory and immune disorders | GLAXO GROUP LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| US-9149462-B2 | Pyrazole compounds acting against allergic, inflammatory and immune disorders | GLAXO GROUP LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| EP-2630126-B1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, IMMUNE AND INFLAMMATORY CONDITIONS | GLAXO GROUP LTD (GB) | 2015-01-07 | — | — | EP | disclosed |
| EP-2630126-B1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, IMMUNE AND INFLAMMATORY CONDITIONS | GLAXO GROUP LTD (GB) | 2015-01-07 | — | — | EP | disclosed |
| US-20130217658-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 2013-08-22 | — | — | US | disclosed |
| US-20130217658-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 2013-08-22 | — | — | US | disclosed |
| US-20130217658-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 2013-08-22 | — | — | US | disclosed |
| US-20130203705-A1 | Pyrazole Compounds Acting Against Allergic, Immune and Inflammatory Conditions | GLAXO GROUP LIMITED (GB) | 2013-08-08 | — | — | US | disclosed |
| US-20130203705-A1 | Pyrazole Compounds Acting Against Allergic, Immune and Inflammatory Conditions | GLAXO GROUP LIMITED (GB) | 2013-08-08 | — | — | US | disclosed |
| WO-2012052459-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203705-A1 | Pyrazole Compounds Acting Against Allergic, Immune and Inflammatory Conditions | NLRP3, IL33, IL5 | POLB 4371/4885KMT2A 2244/4885STIM1 1530/4885 |
| US-20130217658-A1 | PYRAZOLE COMPOUNDS ACTING AGAINST ALLERGIC, INFLAMMATORY AND IMMUNE DISORDERS | NLRP3, IL33, IL5 | POLB 4322/4885KMT2A 2158/4885STIM1 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.